^
    Back
    Association details:
    Biomarker:PIK3CA E545K
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    JAMA Otolaryngol Head Neck Surg
    Title:

    Response of Head and Neck Squamous Cell Carcinoma Cells Carrying PIK3CA Mutations to Select Targeted Therapies

    Excerpt:
    ...we also tested the response of our engineered cell lines to trametinib, which is a selective inhibitor of MEK 1/MEK2 activation and kinase activity. Similar to the trends with 17-AAG and GDC-0941, E545K- and H1047R-SCC25 cells exhibited decreased sensitivity to trametinib
    DOI:
    10.1001/jamaoto.2015.0471